Standout Papers

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors ... 2018 2026 2020 2023 493
  1. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (2018)
    Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology

Immediate Impact

1 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Alessandro Bertolini being referenced

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
2018 Standout

Author Peers

Author Last Decade Papers Cites
Alessandro Bertolini 504 516 10 123 22 736
Vishram B. Rege 481 448 29 96 19 820
A.R. Abdul Razak 429 279 15 206 26 737
J.-L. Canon 477 196 83 92 22 673
N. Vardakis 624 412 22 161 33 754
Kei Takamura 443 550 4 178 40 753
Jean Philippe Spano 409 352 26 151 16 794
Hongbing Liu 368 369 18 168 48 633
Ketki Tendulkar 335 253 63 162 22 618
Frank Peters 417 315 38 75 32 731
Andrea Mancuso 426 291 48 198 35 710

All Works

Loading papers...

Rankless by CCL
2026